Changes in novel biomarkers of disease activity in juvenile and adult dermatomyositis are sensitive biomarkers of disease course

Arthritis and Rheumatism

Volumn 64, Issue 12, 2012, Pages 4078-4086

  Reed, Ann M ^a   Peterson, Erik ^b   Bilgic, Hatice ^b   Ytterberg, Steven R ^a   Amin, Shreyasee ^a   Hein, Molly S ^a   Crowson, Cynthia S ^a   Ernste, Floranne ^a   Gillespie, Emily Baechler ^b  

^a MAYO CLINIC   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CXCL11 CHEMOKINE; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERFERON; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 13; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; INTERLEUKIN 8; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MONOCYTE CHEMOTACTIC PROTEIN 1; MONOCYTE CHEMOTACTIC PROTEIN 2; TUMOR NECROSIS FACTOR ALPHA;

ADOLESCENT; ADULT; ADULT DERMATOMYOSITIS; ADULT DISEASE; AGED; ARTICLE; BLOOD; CHILD; DERMATOMYOSITIS; DISEASE ACTIVITY; DISEASE COURSE; FEMALE; GENE EXPRESSION; HUMAN; JUVENILE DERMATOMYOSITIS; MAJOR CLINICAL STUDY; MALE; PRESCHOOL CHILD; PRIORITY JOURNAL; PROSPECTIVE STUDY; SCHOOL CHILD; VISUAL ANALOG SCALE;

ADOLESCENT; ADULT; AGED; BIOLOGICAL MARKERS; CHEMOKINES; CHILD; CHILD, PRESCHOOL; DERMATOMYOSITIS; DISEASE PROGRESSION; FEMALE; HUMANS; INTERFERON TYPE I; INTERLEUKIN-6; INTERLEUKIN-8; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; TUMOR NECROSIS FACTOR-ALPHA; UP-REGULATION; YOUNG ADULT;

EID: 84870345873     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.34659     Document Type: Article

References (26)

1. Miller FW, Rider LG, Chung YL, Cooper R, Danko K, Farewell V, et al. Proposed preliminary core set measures for disease outcome assessment in adult and juvenile idiopathic inflammatory myopathies. Rheumatology (Oxford) 2001; 40: 1262-73.
2. Rider LG, Miller FW,. Classification and treatment of the juvenile idiopathic inflammatory myopathies. Rheum Dis Clin North Am 1997; 23: 619-55. (Pubitemid 27397123)
3. Baechler EC, Bauer JW, Slattery CA, Ortmann WA, Espe KJ, Novitzke J, et al. An interferon signature in the peripheral blood of dermatomyositis patients is associated with disease activity. Mol Med 2007; 13: 59-68. (Pubitemid 46786834)
4. Zhou X, Dimachkie MM, Xiong M, Tan FK, Arnett FC,. cDNA microarrays reveal distinct gene expression clusters in idiopathic inflammatory myopathies. Med Sci Monit 2004; 10: BR191-7. (Pubitemid 38988162)
5. Bilgic H, Ytterberg SR, Amin S, McNallan KT, Wilson JC, Koeuth T, et al. Interleukin-6 and type I interferon-regulated genes and chemokines mark disease activity in dermatomyositis. Arthritis Rheum 2009; 60: 3436-46.
6. Bohan A, Peter JB,. Polymyositis and dermatomyositis (second of two parts). N Engl J Med 1975; 292: 403-7.
7. Bohan A, Peter JB,. Polymyositis and dermatomyositis (first of two parts). N Engl J Med 1975; 292: 344-7.
8. Isenberg DA, Allen E, Farewell V, Ehrenstein MR, Hanna MG, Lundberg IE, et al, for the International Myositis and Clinical Studies Group (IMACS). International consensus outcome measures for patients with idiopathic inflammatory myopathies: development and initial validation of myositis activity and damage indices in patients with adult onset disease. Rheumatology (Oxford) 2004; 43: 49-54. (Pubitemid 38088368)
9. Rider LG, Giannini EH, Brunner HI, Ruperto N, James-Newton L, Reed AM, et al, for the International Myositis Assessment and Clinical Studies Group. International consensus on preliminary definitions of improvement in adult and juvenile myositis. Arthritis Rheum 2004; 50: 2281-90. (Pubitemid 38924407)
10. Rider LG, Koziol D, Giannini EH, Jain MS, Smith MR, Whitney-Mahoney K, et al. Validation of manual muscle testing and a subset of eight muscles for adult and juvenile idiopathic inflammatory myopathies. Arthritis Care Res (Hoboken) 2010; 62: 465-72.
11. Lovell DJ, Lindsley CB, Rennebohm RM, Ballinger SH, Bowyer SL, Giannini EH, et al, in cooperation with the Juvenile Dermatomyositis Disease Activity Collaborative Study Group. Development of validated disease activity and damage indices for the juvenile idiopathic inflammatory myopathies. II. The Childhood Myositis Assessment Scale (CMAS): a quantitative tool for the evaluation of muscle function. Arthritis Rheum 1999; 42: 2213-9. (Pubitemid 30263608)
12. Baechler EC, Batliwalla FM, Karypis G, Gaffney PM, Ortmann WA, Espe KJ, et al. Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc Natl Acad Sci U S A 2003; 100: 2610-5. (Pubitemid 36297546)
13. Bloom BJ, Tucker LB, Miller LC, Schaller JG,. von Willebrand factor in juvenile dermatomyositis. J Rheumatol 1995; 22: 320-5.
14. Culton DA, O'Conner BP, Conway KL, Diz R, Rutan J, Vilen BJ, et al. Early preplasma cells define a tolerance checkpoint for autoreactive B cells. J Immunol 2006; 176: 790-802. (Pubitemid 43099675)
15. Adams EM, Kirkley J, Eidelman G, Dohlman J, Plotz PH,. The predominance of β (CC) chemokine transcripts in idiopathic inflammatory muscle diseases. Proc Assoc Am Physicians 1997; 109: 275-85. (Pubitemid 27209034)
16. Civatte M, Bartoli C, Schleinitz N, Chetaille B, Pellissier JF, Figarella-Branger D,. Expression of the β chemokines CCL3, CCL4, CCL5 and their receptors in idiopathic inflammatory myopathies. Neuropathol Appl Neurobiol 2005; 31: 70-9. (Pubitemid 40222827)
17. Rider LG, Schiffenbauer AS, Zito M, Lim KL, Ahmed A, Zemel LS, et al. Neopterin and quinolinic acid are surrogate measures of disease activity in the juvenile idiopathic inflammatory myopathies. Clin Chem 2002; 48: 1681-8.
18. De Benedetti F, De Amici M, Aramini L, Ruperto N, Martini A,. Correlation of serum neopterin concentrations with disease activity in juvenile dermatomyositis. Arch Dis Child 1993; 69: 232-5. (Pubitemid 23267370)
19. Ishii W, Matsuda M, Shimojima Y, Itoh S, Sumida T, Ikeda S,. Flow cytometric analysis of lymphocyte subpopulations and Th1/Th2 balance in patients with polymyositis and dermatomyositis. Intern Med 2008; 47: 1593-9.
20. De Bleecker JL, De Paepe B, Vanwalleghem IE, Schroder JM,. Differential expression of chemokines in inflammatory myopathies. Neurology 2002; 58: 1779-85. (Pubitemid 34663578)
21. Niewold TB, Kariuki SN, Morgan GA, Shrestha S, Pachman LM,. Elevated serum interferon-α activity in juvenile dermatomyositis: associations with disease activity at diagnosis and after thirty-six months of therapy. Arthritis Rheum 2009; 60: 1815-24.
22. Krol P, Krystufkova O, Polanska M, Mann H, Klein M, Beran O, et al. Serum levels of interferon α do not correlate with disease activity in patients with dermatomyositis/polymyositis. Ann Rheum Dis 2011; 70: 879-80.
23. Liao AP, Salajegheh M, Nazareno R, Kagan JC, Jubin RG, Greenberg SA,. Interferon β is associated with type 1 interferon-inducible gene expression in dermatomyositis. Ann Rheum Dis 2011; 70: 831-6.
24. Chevrel G, Page G, Granet C, Streichenberger N, Varennes A, Miossec P,. Interleukin-17 increases the effects of IL-1β on muscle cells: arguments for the role of T cells in the pathogenesis of myositis. J Neuroimmunol 2003; 137: 125-33. (Pubitemid 36351574)
25. Walsh RJ, Kong SW, Yao Y, Jallal B, Kiener PA, Pinkus JL, et al. Type I interferon-inducible gene expression in blood is present and reflects disease activity in dermatomyositis and polymyositis. Arthritis Rheum 2007; 56: 3784-92. (Pubitemid 350100711)
26. Lopez de Padilla CM, Vallejo AN, McNallan KT, Vehe R, Smith SA, Dietz AB, et al. Plasmacytoid dendritic cells in inflamed muscle of patients with juvenile dermatomyositis. Arthritis Rheum 2007; 56: 1658-68. (Pubitemid 46764095)